GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Current Ratio

Telo Genomics (Telo Genomics) Current Ratio : 5.07 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Telo Genomics's current ratio for the quarter that ended in Dec. 2023 was 5.07.

Telo Genomics has a current ratio of 5.07. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Telo Genomics's Current Ratio or its related term are showing as below:

TDSGF' s Current Ratio Range Over the Past 10 Years
Min: 0.06   Med: 10.7   Max: 157.75
Current: 5.07

During the past 12 years, Telo Genomics's highest Current Ratio was 157.75. The lowest was 0.06. And the median was 10.70.

TDSGF's Current Ratio is ranked better than
81.93% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.245 vs TDSGF: 5.07

Telo Genomics Current Ratio Historical Data

The historical data trend for Telo Genomics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Current Ratio Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 2.94 33.10 14.71 10.14

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.45 7.13 10.14 11.22 5.07

Competitive Comparison of Telo Genomics's Current Ratio

For the Diagnostics & Research subindustry, Telo Genomics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Current Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Current Ratio falls into.



Telo Genomics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Telo Genomics's Current Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Current Ratio (A: Jun. 2023 )=Total Current Assets (A: Jun. 2023 )/Total Current Liabilities (A: Jun. 2023 )
=2.14/0.211
=10.14

Telo Genomics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=1.091/0.215
=5.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics  (OTCPK:TDSGF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Telo Genomics Current Ratio Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.